The CONTROL NETs trial in neuroendocrine tumours (NETs) has finished patient accrual and is now in follow-up.
NETs are rare cancers that develop in different locations throughout the body in neuroendocrine cells, including the gastro-intestinal tract and the pancreas. NETs that have metastised are currently incurable.
CONTROL NETs is investigating whether chemotherapy, radiopeptide therapy or a combination of both is the most promising treatment for improving disease control in patients with advanced NETs. The study has recruited 75 patients with pancreatic or small bowel NETs. Patients were randomised to receive either capecitabine (chemotherapy)/LuTate (radiopeptide), just capecitabine, or just LuTate.
“Completing patient accrual is an important milestone both for this trial and for the AGITG, in demonstrating the ability to develop and complete accrual to a study in a such a timely fashion in an uncommon but increasingly more prevalent disease,” says the trial’s Principal Investigator, Associate Professor Nick Pavlakis. “The study is hoped to lead to significant learnings to assist the future treatment of patients with neuroendocrine tumours.
“I look forward to sharing the results of the trial in the future.”